Sigma receptors: Potential targets for a new class of antidepressant drug
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Despite the widespread and devastating impact of depression on society, our current understanding of its pathogenesis is limited. Likewise, existing treatments are inadequate, providing relief to only a subset of people suffering from depression. The search for more effective antidepressant drugs includes the investigation of new molecular targets. Among them, current data suggests that sigma receptors are involved in multiple processes effecting antidepressant-like actions in vivo and in vitro. This review summarizes accumulated evidence supporting a role for sigma receptors in antidepressant effects and provides a conceptual framework for delineating their potential roles over the course of antidepressant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“Blocking neurogenesis can prevent the positive behavioral effects of antidepressants in animal models (Santarelli et al., 2003), suggesting that it can be an important component in the mechanism of antidepressant treatment (Perera et al., 2007; Sahay and Hen, 2007).”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241 · cited 2×
“…brain, they are found in significant concentrations in limbic and endocrine areas that have been implicated in the pathophysiology of depression (Drevets et al., 2008; aan het Rot et al., 2009), including the hippocampus, frontal cortex, hypothalamus, and olfactory bulb (Itzhak et al., 1985;…”
BackgroundA molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 1×
“…drugs, where increases in BDNF expression occur concomitantly with significant increases in hippocampal trkB mRNA and TrkB receptor expression (Nibuya et al., 1995), there appears to be a dissociation between the two endpoints for sigma receptor-mediated effects, where increases in…”
BackgroundThe mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Hayashi, T., & Su, T.-P. (2007) · Cell · doi:10.1016/j.cell.2007.08.036 · Cited by 1,826 · cited 3×
“P A A uthor M anuscript The sigma-1 receptor modulates intracellular Ca2+ primarily through interactions with IP3 receptors on the ER and through interactions with Ca2+ channels on the plasma membrane (Hayashi et al., 2000; Hayashi and Su, 2007; Martina et al., 2007).”
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 7×
“Major problems of existing antidepressant drugs include delayed clinical benefit, serious side effects, and a response in less than 50% of patients (Berton and Nestler, 2006).”
BackgroundInfluentialCost of Lost Productive Work Time Among US Workers With Depression
Stewart, W. F. (2003) · JAMA · doi:10.1001/jama.289.23.3135 · Cited by 1,421
New insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · cited 7×
“Additional evidence supporting a role for BDNF in antidepressant activity is provided by the observation that antidepressant drugs are ineffective in the FST in BDNF knockout mice and in TrkB-T1 transgenic mice which overexpress a truncated TrkB receptor (Martinowich et al., 2007).”
BackgroundInfluentialAdult hippocampal neurogenesis in depression
Sahay, A., & Hen, R. (2007) · Nature Neuroscience · doi:10.1038/nn1969 · Cited by 1,206 · cited 2×
“Blocking neurogenesis can prevent the positive behavioral effects of antidepressants in animal models (Santarelli et al., 2003), suggesting that it can be an important component in the mechanism of antidepressant treatment (Perera et al., 2007; Sahay and Hen, 2007).”
BackgroundThe cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800
Cellular changes in the postmortem hippocampus in major depression
Stockmeier, C. A., Mahajan, G. J., Konick, L. C., Overholser, J. C., Jurjus, G. J., Meltzer, H. Y., Uylings, H. B. M., Friedman, L., & Rajkowska, G. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.022 · Cited by 732 · cited 1×
“…et al., 2003), and the importance of the hippocampus to depression pathophysiology (Duman et al., 1997; Nestler et al., 2002; Sheline et al., 2003; Stockmeier et al., 2004; Hercher et al., 2009), these data suggest a potential mechanism through which sigma receptors may promote therapeutically…”
BackgroundScharfman, H., Goodman, J., Macleod, A., Phani, S., Antonelli, C., & Croll, S. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.016 · Cited by 719 · cited 2×
“Continuous infusion of BDNF in the hippocampus of adult rats for two weeks results in the proliferation of newly formed hippocampal neurons (Scharfman et al., 2005).”
BackgroundAntidepressants increase neural progenitor cells in the human hippocampus
Boldrini, M., Underwood, M. D., Hen, R., Rosoklija, G. B., Dwork, A. J., John Mann, J., & Arango, V. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.75 · Cited by 686 · cited 1×
“More recently, SSRI- and TCA-induced increases in neural progenitor cells in the dentate gyrus of humans was reported (Boldrini et al., 2009).”
BackgroundThe pharmacology of sigma-1 receptors.
Maurice, T., & Su, T.-P. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.001 · Cited by 654 · cited 2×
“Functionally, sigma-1 receptors appear to operate primarily via protein-protein interactions and have been shown to modulate the activity of various ion channels and signaling molecules (Maurice and Su, 2009).”
BackgroundRole of Neurotrophic Factors in the Etiology and Treatment of Mood Disorders
Duman, R. S. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:1:011 · Cited by 537
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535 · cited 3×
“However, a number of candidates have been proposed including some neuroactive steroids, sphingolipids (Su et al., 1988; Ramachandran et al., 2009), and most recently N,Ndimethyltryptamine (DMT) (Fontanilla et al., 2009).”
BackgroundRegulation of adult neurogenesis by antidepressant treatment
Duman, R. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00358-x · Cited by 463
Glutamate and Depression: Clinical and Preclinical Studies
PAUL, I. A., & SKOLNICK, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.016 · Cited by 408 · cited 1×
“…glutamatergic signaling in general, are compromised in depression, and that modulation of glutamatergic neurotransmission contributes to the therapeutic effects of antidepressant drugs (Skolnick, 2002; Paul and Skolnick, 2003; Hashimoto, 2009; Machado-Vieira et al., 2009b; Skolnick et al., 2009).”
BackgroundNeuroplasticity Mediated by Altered Gene Expression
McClung, C. A., & Nestler, E. J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301544 · Cited by 347 · cited 2×
“…changes in interneuronal transmission, intracellular signaling and neuronal structure that may accompany antidepressant treatment (Duman, 2004; Dranovsky and Hen, 2006; Warner-Schmidt and Duman, 2006; Dougherty and Rauch, 2007; Tanis and Duman, 2007; Tanis et al., 2007; McClung and Nestler, 2008).”
BackgroundRantamäki, T., Hendolin, P., Kankaanpää, A., Mijatovic, J., Piepponen, P., Domenici, E., Chao, M. V., Männistö, P. T., & Castrén, E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301345 · Cited by 305
Tardito, D., Perez, J., Tiraboschi, E., Musazzi, L., Racagni, G., & Popoli, M. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.7 · Cited by 303 · cited 1×
“A number of antidepressant drugs have been shown to regulate CREB (Carlezon et al., 2005; Nair and Vaidya, 2006; Tardito et al., 2006; Gass and Riva, 2007), which has been implicated in the expression of numerous genes involved in neuroplasticity and cell survival, including growth factors, which…”
BackgroundChaki, S., Yoshikawa, R., Hirota, S., Shimazaki, T., Maeda, M., Kawashima, N., Yoshimizu, T., Yasuhara, A., Sakagami, K., Okuyama, S., et al. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.10.009 · Cited by 254
Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain
Narita, N., Hashimoto, K., Tomitaka, S.-I., & Minabe, Y. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00254-3 · Cited by 254
Cellular and molecular mechanisms in the long-term action of antidepressants.
Racagni, G., & Popoli, M. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/gracagni · Cited by 192 · cited 7×
“Consequently, the term “hypothesis of neuroplasticity” has been proposed to capture the diversity of these dynamic changes (Racagni and Popoli, 2008).”
BackgroundInfluentialMood disorders: Regulation by metabotropic glutamate receptors
Pilc, A., Chaki, S., Nowak, G., & Witkin, J. M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.021 · Cited by 163 · cited 1×
“Antidepressant-like effects have also been observed in rodents following antagonism of metabotropic glutamate receptors (Kugaya, 2005; Pilc et al., 2008; Hashimoto, 2009).”
BackgroundYagasaki, Y., Numakawa, T., Kumamaru, E., Hayashi, T., Su, T.-P., & Kunugi, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508157200 · Cited by 122 · cited 4×
“Evidence for the participation of sigma-1 receptors in these effects include: antagonism of imipramineinduced potentiation with the sigma-1 receptor antagonist BD1047, and enhancement of potentiation in cell cultures overexpressing sigma-1 receptors (Yagasaki et al., 2006).”
BackgroundInfluential
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
“Sigma receptors are promising targets for antidepressant treatment (Fishback et al., 2010), and activation of these receptors induces antidepressant behavioral responses in animals (Matsuno et al.”
BackgroundThe sigma-1 receptor chaperone as an inter-organelle signaling modulator
Su, T.-P., Hayashi, T., Maurice, T., Buch, S., & Ruoho, A. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.007 · Cited by 466
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Walczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
The sigma-1 receptor: roles in neuronal plasticity and disease
Kourrich, S., Su, T.-P., Fujimoto, M., & Bonci, A. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.09.007 · Cited by 245
Metadata
- Authors
- Fishback, J. A., Robson, M. J., Xu, Y.-T., & Matsumoto, R. R.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 127
- Issue
- 3
- Pages
- 271-282
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1975706042
- Cited by
- 125
- References
- 36
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.